Lysteda
| Product Specs | Description |
|---|---|
| Manufacturer Name | Ferring |
| Indications | Tranexamic acid, USP, is an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding. |
| Contraindications | Not for use in patients with congenital factor XIII B-subunit Deficiency. Hypersensitivity to the active substance or to any of the excipients. |
| Manufacturing Methods | Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine with antifibrinolytic properties. |
| Viral Safety Process | Chromatography steps, including hydrophobic interaction and ion exchange chromatography |
| Route of Administration | Oral or intravenous administration |
| Product Half-Life | 11.08 ± 1.9 hours |
| Storage Requirements/Shelf Life |
|
| Available Formulations | 650 mg tablets 100 mg/mL for intravenous injection |